Predictive value of 18F-FDG PET/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner/center study with external validation
- PMID: 36808002
- DOI: 10.1007/s00259-023-06150-2
Predictive value of 18F-FDG PET/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner/center study with external validation
Abstract
Purpose: To develop and validate the predictive value of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) model for breast cancer neoadjuvant chemotherapy (NAC) efficacy based on the tumor-to-liver ratio (TLR) radiomic features and multiple data pre-processing methods.
Methods: One hundred and ninety-three breast cancer patients from multiple centers were retrospectively included in this study. According to the endpoint of NAC, we divided the patients into pathological complete remission (pCR) and non-pCR groups. All patients underwent 18F-FDG PET/CT imaging before NAC treatment, and CT and PET images volume of interest (VOI) segmentation by manual segmentation and semi-automated absolute threshold segmentation, respectively. Then, feature extraction of VOI was performed with the pyradiomics package. A total of 630 models were created based on the source of radiomic features, the elimination of the batch effect approach, and the discretization method. The differences in data pre-processing approaches were compared and analyzed to identify the best-performing model, which was further tested by the permutation test.
Results: A variety of data pre-processing methods contributed in varying degrees to the improvement of model effects. Among them, TLR radiomic features and Combat and Limma methods that eliminate batch effects could enhance the model prediction overall, and data discretization could be used as a potential method that can further optimize the model. A total of seven excellent models were selected and then based on the AUC of each model in the four test sets and their standard deviations, we selected the optimal model. The optimal model predicted AUC between 0.7 and 0.77 for the four test groups, with p-values less than 0.05 for the permutation test.
Conclusion: It is necessary to enhance the predictive effect of the model by eliminating confounding factors through data pre-processing. The model developed in this way is effective in predicting the efficacy of NAC for breast cancer.
Keywords: 18F-FDG PET/CT; Breast cancer; Neoadjuvant chemotherapy; Radiomics.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients.Radiol Med. 2025 Apr;130(4):543-554. doi: 10.1007/s11547-025-01958-4. Epub 2025 Jan 28. Radiol Med. 2025. PMID: 39875749 Free PMC article.
-
18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients.Eur J Nucl Med Mol Imaging. 2020 May;47(5):1116-1126. doi: 10.1007/s00259-020-04684-3. Epub 2020 Jan 25. Eur J Nucl Med Mol Imaging. 2020. PMID: 31982990
-
Intra and peritumoral PET radiomics analysis to predict the pathological response in breast cancer patients receiving neoadjuvant chemotherapy.Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024 May-Jun;43(3):500002. doi: 10.1016/j.remnie.2024.500002. Epub 2024 Mar 23. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024. PMID: 38527731
-
Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Breast Cancer Res. 2020 Oct 31;22(1):119. doi: 10.1186/s13058-020-01350-2. Breast Cancer Res. 2020. PMID: 33129348 Free PMC article.
-
¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.Eur J Nucl Med Mol Imaging. 2016 May;43(5):983-993. doi: 10.1007/s00259-015-3295-z. Epub 2016 Jan 13. Eur J Nucl Med Mol Imaging. 2016. PMID: 26758726 Review.
Cited by
-
Pretreatment multiparametric MRI radiomics-integrated clinical hematological biomarkers can predict early rapid metastasis in patients with nasopharyngeal carcinoma.BMC Cancer. 2024 Apr 8;24(1):435. doi: 10.1186/s12885-024-12209-6. BMC Cancer. 2024. PMID: 38589858 Free PMC article.
-
MRI-based intratumoral and peritumoral radiomics for preoperative prediction of glioma grade: a multicenter study.Front Oncol. 2024 May 13;14:1401977. doi: 10.3389/fonc.2024.1401977. eCollection 2024. Front Oncol. 2024. PMID: 38803534 Free PMC article.
-
Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET/CT radiomics.Cancer Imaging. 2025 May 12;25(1):62. doi: 10.1186/s40644-025-00880-2. Cancer Imaging. 2025. PMID: 40355910 Free PMC article.
-
Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on 18F-FDG PET/CT.J Cancer Res Clin Oncol. 2024 Nov 2;150(11):484. doi: 10.1007/s00432-024-05987-w. J Cancer Res Clin Oncol. 2024. PMID: 39488636 Free PMC article.
-
Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT.Eur J Nucl Med Mol Imaging. 2025 May 6. doi: 10.1007/s00259-025-07306-y. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40325259
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492 . - DOI - PubMed
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654 . - DOI - PubMed
-
- Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R, et al. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019;46:1468–77. https://doi.org/10.1007/s00259-019-04313-8 . - DOI - PubMed
-
- Mao N, Shi Y, Lian C, Wang Z, Zhang K, Xie H, et al. Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on contrast-enhanced spectral mammography. Eur Radiol. 2022;32:3207–19. https://doi.org/10.1007/s00330-021-08414-7 . - DOI - PubMed
-
- Jiang M, Li CL, Luo XM, Chuan ZR, Lv WZ, Li X, et al. Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer. 2021;147:95–105. https://doi.org/10.1016/j.ejca.2021.01.028 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical